Microscopic Remission: What It Is, Why It Matters, and How to Get There
For most people, the word remission conjures a single hope: the cancer is gone. It's what every patient, family member, and practitioner wants to hear. And yet, buried beneath that one word are a dozen assumptions — assumptions that can cost people their lives.
In conventional oncology, remission is usually determined by what’s visible: a clear scan, a stable tumour marker, an absence of symptoms. In particular, the designation “NED” — No Evidence of Disease — is presented as a kind of finish line. It means that based on imaging and standard lab testing, there is no detectable tumour burden.
But this standard of remission, while comforting, is far from comprehensive. Because cancer is not just a tumour. It's not even just a collection of rapidly dividing cells. It is a systemic, adaptive, and often microscopic phenomenon. And in many cases, what remains after a tumour has been “cleared” is far more dangerous than the tumour itself.
Beyond the Scan: What Remission Misses
What standard imaging and blood tests often fail to detect are circulating tumour cells (CTCs) and, more critically, circulating cancer stem cells (CSCs).
Cancer stem cells represent a small subset of the overall tumour population, yet they are disproportionately responsible for relapse, metastasis, and treatment resistance. These cells are uniquely capable of self-renewal, differentiation, and surviving even the most aggressive chemo or radiation protocols. They can lie dormant for years, shielded in protective tissue niches or circulating quietly through the bloodstream, undetectable by conventional means.
So while a scan might show no evidence of disease, the presence of even a small number of CSCs represents a very real — and potentially life-threatening — risk. In fact, many relapses occur not because the treatment “failed” to kill the original tumour, but because the treatments never addressed the root cellular drivers in the first place.
This is the problem with tumour-centric thinking. It focuses on what is visible, rather than what is foundational. And it’s exactly why a growing number of clinicians and patients are shifting their focus toward a more accurate and biologically meaningful outcome: microscopic remission.
What Is Microscopic Remission?
Microscopic remission is not a vague wellness concept. It is a measurable, achievable physiological state in which:
No circulating tumour cells (CTCs) are detectable
No circulating cancer stem cells (CSCs) are measurable
Inflammatory and metabolic markers associated with cancer progression are normalised
The systemic environment (terrain) is non-permissive to cancer cell survival or re-emergence
In short, microscopic remission means there is no detectable microscopic evidence of the biological drivers of cancer.
Where standard remission is determined by what can be seen or felt, microscopic remission is about what can be measured at the cellular and metabolic level — often through specialised pathology testing not yet standardised in mainstream care.
This is not semantics. It’s the difference between apparent stability and actual resolution.
Functional Evidence: It Is Possible
In recent weeks, I’ve received pathology results from two patients — both of whom followed a structured integrative metabolic strategy. One of them had been diagnosed with pancreatic cancer, one of the most difficult cancers to manage in conventional oncology. Both of them now show zero detectable circulating cancer stem cells.
Not low.
Not borderline.
Zero.
These aren’t miracles. They are outcomes grounded in evidence-informed, consistent, multifaceted metabolic care. They represent what’s possible when we stop treating cancer as a tumour and start treating it as a complex systemic condition — one that requires a systems-level intervention.
Why Are CSCs Missed by Conventional Care?
There are several reasons why CSCs remain outside the scope of standard treatment:
They represent a minority population. CSCs are often less than 1% of a tumour’s cellular mass, making them invisible on imaging and unlikely to be captured by bulk tissue biopsy.
They are metabolically unique. CSCs have different mitochondrial dynamics, redox buffering systems, and nutrient dependencies compared to the bulk tumour.
They resist standard treatments. Chemotherapy and radiotherapy may shrink the tumour but often leave CSCs untouched — or worse, enriched by eliminating competing non-stem cancer cells.
There is limited testing infrastructure. While advanced functional tests can now detect CTCs and CSCs in the bloodstream, these are rarely utilised outside of integrative and functional oncology circles.
Getting There: How to Achieve Microscopic Remission
Microscopic remission is not the result of a single drug or a lucky outcome. It requires a structured, strategic, and phased approach that weakens cancer at its roots while strengthening the body’s own capacity to surveil and respond.
This is the core of the Press-Pulse Strategy — a term borrowed from ecological biology and adapted into integrative metabolic oncology. It describes a two-phase system:
Press Phase: Suppression and Sensitisation
The goal here is to weaken CSCs by depriving them of the resources and signalling pathways they rely on.
Key interventions in the Press Phase include:
Methionine and cysteine restriction: Sulfur amino acids are critical for glutathione recycling and redox buffering. Limiting them starves CSCs of their defences.
Fasting and caloric restriction: Periods of fasting reduce IGF-1 and insulin, lower glucose availability, and push CSCs into metabolic vulnerability.
Low-glutamine dietary strategies: Targeting glutamine metabolism further stresses CSCs' survival pathways.
Repurposed medicines: Agents like Metformin, Ivermectin, Doxycycline, and Mebendazole may disrupt key CSC pathways when used strategically.
Nutraceutical disruptors: EGCG, curcumin, resveratrol, and omega-3 fatty acids add metabolic pressure on CSC pathways.
Hyperthermia: Heat-based therapies reduce CSC viability by disrupting mitochondrial function and increasing oxidative stress.
The Press Phase is about priming the system — creating a biological landscape where CSCs are exposed and weakened.
Pulse Phase: Oxidative Onslaught and Cellular Kill
This phase leverages the vulnerabilities exposed during the Press Phase and applies short bursts of oxidative pressure and mitochondrial destabilisation.
Interventions here include:
Ketogenic dietary therapy: Transitioning to a high-fat, very low-carb diet supports healthy cells but adds stress to glucose-addicted CSCs.
Pro-oxidant stacking: High-dose IV Vitamin C, sodium selenite, and therapies like artesunate are used to overwhelm the cancer cell’s antioxidant defences.
Hyperbaric Oxygen Therapy (HBOT): Increases tissue oxygenation, enhancing the effect of oxidative therapies and promoting normal cellular metabolism.
Chemotherapy (in some cases): When timed appropriately, chemo can serve as an effective Pulse intervention — especially when combined with metabolic stressors.
This cyclical strategy mirrors the body’s natural rhythm of rest and activation — gently sensitising cancer cells before targeting them for destruction.
The Role of Nervous System and Terrain
Microscopic remission isn’t just about destroying cancer — it’s about transforming the system that allowed it to take hold. That includes:
Nervous system regulation: Chronic stress upregulates tumour-promoting inflammation and suppresses immune surveillance. Regulating the autonomic nervous system is foundational.
Sleep optimisation and circadian alignment: CSCs are highly sensitive to circadian disruption; restoring natural sleep-wake rhythms helps reinstate immune competence.
Mitochondrial recovery and cellular repair: Microscopic remission is sustained when healthy cells function efficiently and without DNA-damaging inflammation.
We are not simply fighting rogue cells — we are reshaping the ecological conditions of the body itself.
What You Can’t See Can Hurt You
It’s easy to celebrate a clear scan. And in many ways, that celebration is valid — it means you’ve made it through something enormous.
But it must not be mistaken for completion.
Microscopic remission is the real finish line.
And in truth, it’s not the end — it’s the beginning of long-term recovery, terrain stewardship, and deep physiological reorganisation.
Whether you're in treatment, post-treatment, or somewhere in between — know this:
You’re not powerless.
The path to microscopic remission is measurable, possible, and real.
And it’s already being walked by patients who refused to settle for “no evidence.”
Because no evidence is not the same as no disease.
And when we treat the root, we reclaim far more than health.
We reclaim sovereignty.
Medical Disclaimer
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. It should not be used as a substitute for professional medical consultation, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider before making any decisions about your cancer treatment, including dietary changes, metabolic strategies, repurposed medications, or integrative therapies.
Every individual’s medical condition is unique, and what works for one person may not be appropriate for another. Integrating metabolic and conventional oncology approaches should be done under the supervision of a highly experienced health professional who understands the complexity of cancer care and the potential interactions between different treatments.
No guarantees of outcome are expressed or implied, and reliance on any information provided in this article is at your own discretion and risk.
References
Batlle E, Clevers H. (2017). Cancer stem cells revisited. Nature Medicine, 23(10), 1124–1134.
Dean M, Fojo T, Bates S. (2005). Tumour stem cells and drug resistance. Nature Reviews Cancer, 5(4), 275–284.
Phi LTH et al. (2018). Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells International, 2018, 5416923.
Prasetyanti PR, Medema JP. (2017). Intra-tumor heterogeneity from a cancer stem cell perspective. Molecular Cancer, 16(1), 41.
Zhou Y et al. (2020). Cancer stem cells in progression of colorectal cancer. Oncotarget, 11(12), 1070–1081.
López-Lázaro M. (2020). The cancer stem cell theory: a critical appraisal. Archives of Toxicology, 94, 2295–2311.
Seyfried TN, Shelton LM. (2010). Cancer as a metabolic disease. Nutrition & Metabolism, 7(1), 7.
Longo VD, Panda S. (2016). Fasting, circadian rhythms, and time-restricted feeding in healthy lifespan. Cell Metabolism, 23(6), 1048–1059.
Davis C, Bryan J, Hodgson J, Murphy K. (2015). Definition of the Mediterranean diet; a literature review. Nutrients, 7(11), 9139–9153.
Zhou Y, Bollu LR, Tozzi F, Ye X, Bhattacharya R, Gao G, et al. (2014). ATP citrate lyase mediates resistance of colorectal cancer cells to SN38. Molecular Cancer Therapeutics, 13(12), 3204–3216.
Klement RJ. (2017). Fasting, FATS, and physics: Combining ketogenic therapy and fasting to target cancer stem cells. International Journal of Radiation Biology, 93(10), 965–971.
Allen BG et al. (2013). Ketogenic diets enhance oxidative stress and radio-chemo-therapy responses in lung cancer xenografts. Clinical Cancer Research, 19(14), 3905–3913.
Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al. (2017). O2 and ROS-dependent mechanisms of hyperbaric oxygen therapy in cancer treatment. Free Radical Biology and Medicine, 113, 203–210.
Yang M et al. (2020). Methionine restriction selectively targets CSCs and potentiates the effects of oxidative therapies. Cell Metabolism, 31(3), 490–503.
Seyfried TN, Yu G, Maroon JC, D’Agostino DP. (2020). Press-pulse therapeutic strategy for cancer management. Nutrition & Metabolism, 17(1), 1–15.